PLOS ONE vs BMC Medicine
PLOS ONE and BMC Medicine are both open-access options, but PLOS ONE rewards technical validity while BMC Medicine asks for influential medical relevance.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Journal fit
See whether this paper looks realistic for BMC Medicine.
Run the Free Readiness Scan with BMC Medicine as your target journal and see whether this paper looks like a realistic submission.
BMC Medicine at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 8.8 puts BMC Medicine in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~20% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: BMC Medicine takes ~30-45 days. A faster-turnaround journal may suit a grant or job deadline better.
- If OA is required: gold OA costs ~$3,500 USD. Check institutional agreements before submitting.
PLOS ONE vs BMC Medicine at a glance
Use the table to see where the journals diverge before you read the longer comparison. The right choice usually comes down to scope, editorial filter, and the kind of paper you actually have.
Question | PLOS ONE | BMC Medicine |
|---|---|---|
Best fit | PLOS ONE publishes original research from any discipline in the natural sciences,. | BMC Medicine publishes research across all areas of clinical practice, public health,. |
Editors prioritize | Methodological rigor above all else | Methodological rigor that withstands scrutiny |
Typical article types | Research Article, Registered Report | Research Article, Systematic Review |
Closest alternatives | Scientific Reports, PeerJ | PLOS Medicine, BMJ Open |
Quick answer: Choose PLOS ONE when the manuscript is technically sound, ethically complete, clearly reported, and does not need to make a high-impact medical claim. Choose BMC Medicine when the manuscript has broad clinical, translational, public-health, global-health, policy, or biomedical relevance that can plausibly be called influential. The difference is technical validity versus medical influence.
If you want a fast journal-fit read before submission, start with the AI manuscript review. For related decisions, read PLOS ONE vs Scientific Reports and BMC Medicine submission guide.
Method note: this page uses PLOS ONE publication criteria and reviewer guidance, BMC Medicine aims and fees guidance, BMC registered-report guidance, and Manusights medical journal-fit review patterns reviewed in April 2026. This is the canonical comparison page; do not also build bmc-medicine-vs-plos-one.How PLOS ONE And BMC Medicine Compare
Question | PLOS ONE | BMC Medicine |
|---|---|---|
Core editorial question | Is the work technically rigorous, ethical, and clearly reported? | Is the work outstanding and influential for medicine or health? |
Strongest paper | Valid research, including negative or replication work | Broad medical, public health, translational, policy, or global health work |
Scope | Science, medicine, engineering, related social sciences and humanities | General medicine and health |
Common fit mistake | Treating it as a dump for weak methods | Treating it like any broad medical OA journal |
Better first page | Design, methods, data, and supported conclusion | Medical importance and reader consequence |
Best author question | Is this valid and clearly reported? | Does this matter to a broad medical audience? |
Both are open access. That is not the decision.
Which Should You Submit To?
Submit to PLOS ONE if the paper's strongest claim is that the work is rigorous, complete, and worth being part of the scientific record, even if it is not highly novel or high-impact.
Submit to BMC Medicine if the paper's strongest claim is that it matters broadly for clinical practice, public health, health policy, global health, translational medicine, or biomedical decision-making.
This boundary prevents cannibalization with PLOS ONE good-journal pages and BMC Medicine submission pages. This page owns the direct author decision between technical-validity publication and influential general medical publication.
Choose PLOS ONE If / Choose BMC Medicine If
Choose PLOS ONE if the manuscript can pass a rigorous technical and reporting review but is not trying to sell broad medical importance.
Choose BMC Medicine if the manuscript has a real medical consequence beyond one narrow dataset or local setting.
Manuscript pattern | Better first target |
|---|---|
Well-designed negative or replication study | PLOS ONE |
Public-health analysis with broad policy consequence | BMC Medicine |
Technically valid clinical dataset with narrow conclusion | PLOS ONE |
General medical or global health study with wide relevance | BMC Medicine |
Methods or dataset paper with clear reporting | PLOS ONE |
Translational medicine paper with broad biomedical implication | BMC Medicine |
If BMC Medicine feels appealing only because it is more selective, ask whether the medical consequence is visible on page one.
Journal fit
Ready to find out which journal fits? Run the scan for BMC Medicine first.
Run the scan with BMC Medicine as the target. Get a fit signal that makes the comparison concrete.
What PLOS ONE Wants
PLOS ONE's public criteria emphasize original research, no prior publication, high technical standards, sufficient method detail, supported conclusions, intelligible language, ethics, reporting guidelines, and data availability. PLOS ONE reviewer guidance also states that review is focused on technical rigor and scientific and ethical standards, not an editorial importance threshold.
That makes PLOS ONE a good home for solid work that should be published but does not need to clear a major medical influence bar.
PLOS ONE is stronger when:
- the methods are clean
- the conclusion is proportionate
- reporting and data availability are complete
- negative, null, replication, or incremental results are still useful
- the paper is not pretending to be more important than it is
What BMC Medicine Wants
BMC Medicine describes itself as an open-access, transparent peer-reviewed general medical journal publishing outstanding and influential research across clinical practice, translational medicine, medical and health advances, public health, global health, policy, and topics of interest to biomedical and sociomedical communities.
That is a different bar from PLOS ONE. A technically valid paper may still be too narrow for BMC Medicine.
BMC Medicine is stronger when:
- the medical question matters beyond one local group
- the paper has clinical, policy, translational, or public-health consequence
- the first page names a broad medical reader
- reporting is complete enough for transparent review
- the discussion explains why the finding should change interpretation or action
In Our Pre-Submission Review Work
In our pre-submission review work, PLOS ONE vs BMC Medicine decisions usually fail when authors confuse "open access" with "same audience."
BMC Medicine overreach: the paper is valid, but the medical consequence is not broad enough.
PLOS ONE under-positioning: the paper has real public-health or clinical consequence, but the authors choose PLOS ONE to avoid selectivity.
Weak-method shortcut: authors try PLOS ONE after a selective-journal rejection without fixing the methodological reason for rejection.
APC-first targeting: authors compare publication fees before asking which audience is correct.
What To Fix Before Submission
For PLOS ONE, make the methods, data availability, reporting guideline, ethics statement, and conclusion calibration airtight. The paper can be modest, but it cannot be sloppy.
For BMC Medicine, make the broad medical consequence visible in the title, abstract, first table or figure, and discussion. The paper should not read like a narrow specialty result with a general-medicine title.
For both, do not hide limitations. The better page one is honest about what the study can and cannot prove.
Tie-Breaker Cases Editors Notice
The hardest PLOS ONE vs BMC Medicine cases are not weak papers. They are sound papers with unclear ambition. A technically solid observational study, diagnostic analysis, implementation study, or secondary data analysis may fit either route depending on how much the result changes medical understanding.
Choose PLOS ONE when the manuscript's main promise is transparent, reusable, technically sound evidence. The paper can be useful because the dataset is well described, the analysis is reproducible, the negative or null result is informative, or the finding clarifies a narrow question. That is different from asking a general medical audience to treat the result as broadly influential.
Choose BMC Medicine when the manuscript can answer a sharper question: who in medicine or public health should act differently, interpret evidence differently, or investigate differently because of this study? If that answer is not visible in the abstract and discussion, the paper may read as a specialty manuscript wearing a general medicine label.
Before submission, test the claim sentence. If it says "this study may have implications" without naming the decision, population, policy, practice, or biomedical problem, the BMC Medicine case is probably not ready.
Submit If / Think Twice If
Submit to PLOS ONE if:
- the study is technically rigorous
- conclusions are supported by the data
- reporting and data availability are complete
- the work is useful even without a high novelty claim
Submit to BMC Medicine if:
- the work has broad medical or health relevance
- the paper can plausibly influence clinical, policy, public-health, or biomedical thinking
- the abstract states a consequence beyond one narrow niche
- reporting is strong enough for transparent review
Think twice for both if:
- the methods are weak
- the target is chosen mainly by APC or perceived ease
- the first page cannot name the reader
Bottom Line
PLOS ONE is usually the better fit for technically sound broad research that deserves publication without a high-impact medical claim. BMC Medicine is the better fit for research with broad medical, public-health, policy, translational, or biomedical influence.
Use the AI manuscript review if you need a fast read on which journal your manuscript actually supports.
- https://journals.plos.org/plosone/s/criteria-for-publication
- https://journals.plos.org/plosone/s/reviewer-guidelines
- https://journals.plos.org/plosone/s/journal-information
- https://bmcmedicine.biomedcentral.com/submission-guidelines/aims-and-scope
- https://bmcmedicine.biomedcentral.com/submission-guidelines/registered-report
Frequently asked questions
Submit to PLOS ONE when the manuscript is technically sound broad research and does not need to clear a high medical influence bar. Submit to BMC Medicine when the paper has broad clinical, translational, public health, global health, policy, or biomedical relevance.
Usually yes. BMC Medicine describes itself as publishing outstanding and influential research in medicine and health. PLOS ONE evaluates technical rigor, ethics, reporting, and whether conclusions are supported by data.
Sometimes, but only if the paper still satisfies PLOS ONE's technical, ethical, reporting, and data-availability criteria. If the BMC Medicine rejection was about weak methods, PLOS ONE is not a shortcut.
The two pages would answer the same comparison query. Manusights uses one canonical comparison page to avoid cannibalization.
Final step
See whether this paper fits BMC Medicine.
Run the Free Readiness Scan with BMC Medicine as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
Compare alternatives
Supporting reads
Conversion step
See whether this paper fits BMC Medicine.
Anthropic Privacy Partner. Zero-retention manuscript processing.